Niopam (Iopamidol)

Iopamidol works by providing a high concentration of iodine atoms that absorb X‑ray photons. When injected, it temporarily increases the radiodensity of blood or body fluids, creating a contrast between the enhanced area and surrounding tissues. This difference allows imaging systems to produce detailed pictures of vascular and tissue anatomy.

The dose of Niopam is individualized by the prescribing physician based on the specific imaging study, patient size, renal function and the vascular territory to be examined. Healthcare professionals calculate the appropriate volume and concentration to achieve optimal image quality while minimizing exposure.

The safety of iopamidol in pregnancy and lactation has not been definitively established. It should only be used when the diagnostic benefit outweighs potential risks, and the decision must be made by the treating physician in consultation with the patient. Breastfeeding mothers should discuss possible exposure with their healthcare provider.

To request Niopam, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Niopam (iopamidol) is a non‑ionic, low‑osmolality contrast medium, offering a lower incidence of adverse reactions compared with older ionic agents. Its safety profile, especially regarding renal tolerance and allergic potential, is comparable to other modern agents such as iohexol or iopromide, while providing similar image enhancement quality.

Niopam should be stored at ambient temperature, below 25 °C, in its original sealed container. Protect the solution from direct sunlight, excessive heat and moisture. Do not freeze or shake the vial; inspect for particulate matter before use and discard any solution that appears discolored or contaminated.

Niopam is supplied as a sterile solution for injection and is administered intravenously, intra‑arterially, intra‑articularly or intracisternally, depending on the imaging procedure. The injection is performed by qualified healthcare personnel using aseptic technique, with the volume and rate determined by the imaging protocol and patient characteristics.

The most serious risks include severe allergic reactions such as anaphylaxis, contrast‑induced nephropathy leading to acute renal failure, and rare cardiovascular events like arrhythmias or cardiopulmonary arrest. Prompt recognition and emergency management are essential if any of these reactions occur during or after administration.

Niopam is contraindicated in patients with a known hypersensitivity to iopamidol or any iodinated contrast media, those with uncontrolled hyperthyroidism, and individuals with severe renal impairment where alternative imaging strategies are feasible. Clinicians should also exercise caution in patients with a history of severe allergic reactions to other contrast agents.